Mitsubishi Tanabe Pharma Corporation

Sanofi

Daiki Sakai

Kazutoshi Watanabe

Kazuki Nakayama

Toshiyuki Kohara

Kenji Fukunaga

Fumiaki Uehara

Yoshihiro Usui

Keiichi Aritomo

Satoshi Yokoshima

Shin-ichi Kusaka

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C&#x2014;F or the like; Rrepresents a C-Calkyl group;Y represents oxygen atom or N&#x2014;R; R, R, R, R, Rand Reach independently represents hydrogen atom, a C-Calkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

3-[1,4]oxazepane-4-pyrimidone derivatives

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom or C&#x2014;X; X represents hydrogen atom or fluorine atom; Ris hydrogen atom or a C-Calkyl group; L represents single bond or a C-Calkylene group which may be substituted; Y represents single bond, sulfur atom, oxygen atom, NH, or the like; Rrepresents hydrogen atom or a cyclic group which may be substituted, which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

Pyrimidone derivatives

A pyrimidone derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof: wherein X represents hydrogen atom and Y represents hydroxyl group, or X represents fluorine atom and Y represents hydrogen atom; Rrepresents a Calkyl group; Rrepresents a morpholin-4-yl group which may be substituted, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

Pyrimidone compounds

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein Rrepresents a hydrogen or the like; Rrepresents methyl group or the like; Rrepresents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; Rrepresents hydrogen or the like; Rrepresents hydrogen or the like; Rrepresents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH, oxygen atom, NH, or the like; any one or more of Rand R, Rand R, Rand R, X and R, X and R, X and R, and Rand Rmay combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

2-(cyclic amino)-pyrimidone derivatives

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor

Growing community of inventors

Kanagawa, Japan

Daiki Sakai